American Heart Journal
Volume 159, Issue 3 , Pages 370-376, March 2010

In-hospital management of patients with atrial flutter

  • Nancy M. Allen LaPointe, PharmD

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
    • Corresponding Author InformationReprint requests: Nancy M. Allen LaPointe, PharmD, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715.
  • ,
  • Jie-Lena Sun, MS

      Affiliations

    • Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
  • ,
  • Sigal Kaplan, PhD, BPharm

      Affiliations

    • US Food and Drug Administration, Center of Drug Evaluation and Research, Office of Surveillance and Epidemiology, Silver Spring, MD

Received 2 December 2009; accepted 18 December 2009.

Background

Little is known about the use of drugs or procedures for management of atrial flutter (AFl) in routine clinical practice. We describe the extent of use of conversion therapies during AFl hospitalizations.

Methods

We examined hospitalizations for primary diagnoses of AFl using hospital claims from January 2000 to December 2004. Patients who received antiarrhythmic drugs, ablation, and/or electrical cardioversion for AFl were categorized as receiving a conversion therapy. Characteristics associated with use of conversion therapy versus no conversion therapy were determined.

Results

The study cohort included 19,825 hospitalizations. Of these, 13,059 (65.9%) included in-hospital use of ≥1 conversion therapies. Care by a noncardiologist (adjusted odds ratio [OR] 0.37, 95% CI 0.33-0.41), female sex (adjusted OR 0.84, 95% CI 0.79-0.90), nonwhite race (adjusted OR 0.83, 95% CI 0.74-0.92), and increasing age >70 years (adjusted OR 0.88, 95% CI 0.85-0.91) were associated with lower odds of conversion versus no-conversion therapy. Cardiomyopathy (adjusted OR 1.33, 95% CI 1.17-1.51), heart failure (adjusted OR 1.17, 95% CI 1.06-1.28), coronary artery disease (adjusted OR 1.14, 95% CI 1.05-1.22), secondary diagnosis of atrial fibrillation (adjusted OR 1.28, 95% CI 1.18-1.38), and hospitalization in 2000 or 2001 versus later years (adjusted OR 1.22, 95% CI 1.12-1.33) were associated with greater odds of conversion therapy versus no conversion therapy.

Conclusion

One or more methods of conversion to sinus rhythm were used in two thirds of the hospitalizations with a primary diagnosis of AFl. Greater use of conversion therapies in patients with other heart disease were expected; however, lower use among elderly persons, females, and racial minorities may indicate some disparities in use and warrant further study.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-8703(09)00967-3

doi:10.1016/j.ahj.2009.12.013

American Heart Journal
Volume 159, Issue 3 , Pages 370-376, March 2010